Product Details
| Product Name:
Letaplimab |
CAS No.:
2283356-07-8 |
| Purity:
97.4% (SDS-PAGE); 97.2% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2025/12/03 |
Product Introduction
Bioactivity
| Name | Letaplimab |
| Description | Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes. |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Letaplimab | IBI 188 | CD47 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:895127-66-9
$142.00 / 25μg
-
CAS:1310746-10-1
$40.00 / 5mg
-
CAS:149092-50-2
$30.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States